Status:
COMPLETED
Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis
Lead Sponsor:
Shire
Conditions:
Kidney Failure, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with lanthanum carbonate
Eligibility Criteria
Inclusion
- Males and females of childbearing potential agree to take adequate precautions to prevent contraception
- Patients diagnosed with ESRD must have been receiving a stable dialysis regimen for chronic renal failure for the 2 consecutive months prior to enrollment in the study
- Patient requires treatment for hyperphosphataemia
Exclusion
- Pregnant or lactating women
- Patients who continue to require treatment with compounds containing calcium, aluminum or magnesium
- Patients with clinically significant uncontrolled concurrent illness, a life-threatening malignancy or current multiple myeloma
- Patients who are HIV+
- Patients with any significant gastrointestinal surgery or disorders
Key Trial Info
Start Date :
May 11 2004
Trial Type :
INTERVENTIONAL
End Date :
January 12 2006
Estimated Enrollment :
456 Patients enrolled
Trial Details
Trial ID
NCT00151931
Start Date
May 11 2004
End Date
January 12 2006
Last Update
June 8 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.